|
Name |
Histidylproline
|
Molecular Formula | C11H16N4O3 | |
IUPAC Name* |
(2S)-1-[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
|
|
SMILES |
C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)O
|
|
InChI |
InChI=1S/C11H16N4O3/c12-8(4-7-5-13-6-14-7)10(16)15-3-1-2-9(15)11(17)18/h5-6,8-9H,1-4,12H2,(H,13,14)(H,17,18)/t8-,9-/m0/s1
|
|
InChIKey |
LNCFUHAPNTYMJB-IUCAKERBSA-N
|
|
Synonyms |
Histidylproline; His-pro; 20930-58-9; H-His-Pro-OH; histidyl-proline; L-histidyl-L-proline; (2S)-1-[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid; Histidinyl-Proline; Histidinylproline; HP dipeptide; H-P Dipeptide; L-His-L-Pro; L-His-L-Pro-OH; L-Histidinyl-L-Proline; Histidine Proline dipeptide; Histidine-Proline dipeptide; L-Proline, 1-L-histidyl-; SCHEMBL4595209; CHEBI:74055; DTXSID50943211; ZINC5116874; HY-111659; CS-0089268; Q27144368; H-P
|
|
CAS | 20930-58-9 | |
PubChem CID | 152322 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 252.27 | ALogp: | -2.9 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 112.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 18 | QED Weighted: | 0.687 |
Caco-2 Permeability: | -5.846 | MDCK Permeability: | 0.00000720 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.739 |
Human Intestinal Absorption (HIA): | 0.043 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.008 |
Blood-Brain-Barrier Penetration (BBB): | 0.891 | Plasma Protein Binding (PPB): | 7.38% |
Volume Distribution (VD): | 0.384 | Fu: | 97.72% |
CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.126 |
CYP2C19-inhibitor: | 0.039 | CYP2C19-substrate: | 0.059 |
CYP2C9-inhibitor: | 0.013 | CYP2C9-substrate: | 0.535 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.051 |
CYP3A4-inhibitor: | 0.095 | CYP3A4-substrate: | 0.032 |
Clearance (CL): | 6.623 | Half-life (T1/2): | 0.907 |
hERG Blockers: | 0.056 | Human Hepatotoxicity (H-HT): | 0.296 |
Drug-inuced Liver Injury (DILI): | 0.355 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.037 | Maximum Recommended Daily Dose: | 0.061 |
Skin Sensitization: | 0.597 | Carcinogencity: | 0.023 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.022 |
Respiratory Toxicity: | 0.046 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001906 | 0.561 | D08BTB | 0.482 | ||||
ENC000749 | 0.533 | D0I0EG | 0.475 | ||||
ENC000138 | 0.509 | D0N4EC | 0.444 | ||||
ENC001093 | 0.484 | D0N5HJ | 0.352 | ||||
ENC001065 | 0.403 | D00SEB | 0.330 | ||||
ENC001902 | 0.403 | D07HGR | 0.323 | ||||
ENC002115 | 0.362 | D09NYU | 0.319 | ||||
ENC000810 | 0.314 | D0X5SJ | 0.296 | ||||
ENC002436 | 0.247 | D0T8LY | 0.282 | ||||
ENC000140 | 0.211 | D04USC | 0.281 |